CLYM (Climb Bio) 50-Day SMA: $11.15 (As of Jul. 07, 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $13.27
! 3 Warning Signs
View Full Analysis

What is Climb Bio 50-Day SMA?

Climb Bio CLYM +2.87% 22 50-Day SMA is $11.15 as of Jul. 07, 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2026-07-07), Climb Bio's 50-Day SMA is $11.15. It's 20-Day SMA is $11.97 and 200-Day SMA is $6.04.

Climb Bio  (NAS:CLYM) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.

Climb Bio 50-Day SMA Related Terms

CLYM vs XOMA, CTMX, ALLO: 50-Day SMA Comparison

For the Biotechnology subindustry, Climb Bio's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio 50-Day SMA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Climb Bio's 50-Day SMA falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
50-Day SMA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio  (NAS:CLYM) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 50-Day SMA →
What does a 50-Day SMA of $11.15 mean?
Climb Bio (CLYM) has a 50-Day SMA of $11.15 as of Jul. 07, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Climb Bio and its competitors.
Is Climb Bio's 50-Day SMA too high?
Climb Bio's current 50-Day SMA is $11.15. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's 50-Day SMA compare to XOMA and CTMX?
Climb Bio's 50-Day SMA of $11.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Climb Bio and its competitors. Climb Bio's current 50-Day SMA is $11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current 50-Day SMA of $11.15. The current 50-Day SMA is $11.15. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Climb Bio (CLYM), the current 50-Day SMA is $11.15 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.27
Price